Skip to main content

CCTG Connection



Published:
Category: Group updates
2024 Annual Report
The CCTG 2024 Annual Report is now live! 
 
2024 was a highly eventful year for the group, marked by both challenges and significant achievements. The group surpassed expectations in trial activation, launching 18 new studies across early and late phase programs—exceeding our annual target. Funding activity was also strong, with 17 applications submitted and seven successfully awarded, securing $5.9 million in support.
Read More

Published:
Category: Publications
Publication: secondary analysis MAC18
Two secondary analysis for the MAC18 (POSITIVE) trial, one looking at breastfeeding after hormone receptor-positive breast cancer and the other looking at the hormonal factors predictive of fertility in patients with breast cancer. Read More

Published:
Category: Publications
Publication: HNC2 (primary)
HNC2 (NRG-HN004): Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin 
Management of patients with locoregionally advanced head and neck squamous cell carcinoma when cisplatin is contraindicated is controversial.
Read More

Published:
Category: Publications
Publications: General Review
Two general publication, the first is looking at the financial difficulty among patients with cancer participating in clinical trials, the other is an evaluation of the Canadian Remote Access Framework for Clinical Trials (CRAFT) pilot. Read More

Published:
Category: Publications
Publication: secondary analysis CX5 and CO26
Secondary analysis: CX5 surgical approach analysis and the CO26 cost utility analysis Read More

Published:
Category: Trials
Closed to Accrual: HD11

The CCTG HD11 study, a Randomized Phase II Study of Pembrolizumab and Brentuximab Vedotin Versus GDP, Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma  has closed to accrual. This purpose of this study was to determine if treatment with Pembrolizumab and Brentuximab vedotin is better or worse than the standard of care for classical Hodgkin lymphoma.

For more information > CCTG HD11 members trial page.

Read More



Published:
Category: Group updates

CCTG is upgrading our login platform to Auth0 by Okta for a more secure and seamless login experience. The new login screen is designed to be simple and user-friendly, allowing you to log in using your existing credentials. This change ensures faster, more reliable access to your account with fewer sign ins, while keeping your data safe.
 

Read More



Published:
Category: Group updates
Timothy Joseph Whelan, Awarded Officer of the Order of Canada

Please join us in congratulating our friend and colleague, Timothy Whelan on his appointment to the Order of Canada. He is a world-class radiation oncologist and his research has redefined radiation therapy’s use in the treatment of breast cancer, improving survival rates and limiting side effects. He has mentored many trainees, solidifying the reputations of McMaster University and the Juravinski Cancer Centre as leaders in oncology clinical trial training. 

 

Read More